{"id":"NCT01144637","sponsor":"Bavarian Nordic","briefTitle":"A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02","primaryCompletion":"2013-11","completion":"2014-06","firstPosted":"2010-06-15","resultsPosted":"2019-01-03","lastUpdate":"2019-01-03"},"enrollment":4005,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Smallpox"],"interventions":[{"type":"BIOLOGICAL","name":"IMVAMUNE®","otherNames":["IMVANEX","MVA-BN®"]},{"type":"OTHER","name":"Placebo","otherNames":["Tris-buffered-saline"]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"},{"label":"Group 3","type":"EXPERIMENTAL"},{"label":"Group 4","type":"PLACEBO_COMPARATOR"}],"summary":"A randomized, double-blind, placebo-controlled Phase III trial to evaluate immunogenicity and safety of three consecutive production lots of IMVAMUNE® (MVA-BN®) smallpox vaccine in healthy, vaccinia-naïve subjects.","primaryOutcome":{"measure":"PRNT GMT","timeFrame":"2 weeks following the second vaccination","effectByArm":[{"arm":"Group 1","deltaMin":110.7,"sd":null},{"arm":"Group 2","deltaMin":100.5,"sd":null},{"arm":"Group 3","deltaMin":117.2,"sd":null},{"arm":"Group 4","deltaMin":1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":13,"exclusionCount":27},"locations":{"siteCount":34,"countries":["United States"]},"refs":{"pmids":["29652929"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":999},"commonTop":["Upper respiratory tract infection","Injection site induration","Nasopharyngitis","Oropharyngeal pain","Injection site haematoma"]}}